SMMT vs. TECH: Summit Therapeutics vs. Bio-Techne Stock Comparison

Company Profile

Summit Therapeutics (SMMT) and Bio-Techne (TECH) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but SMMT is classified in Biotechnology while TECH is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Bio-Techne (TECH) has a non-negative beta of 1.26.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Techne (TECH) reports 8.33%, ranking against industry peers normally.

Bio-Techne (TECH) at 14.00% retains a top-quartile share of revenue as profit, ahead of Summit Therapeutics (SMMT) at 0.00%, which keeps about the industry-typical share.

Both Summit Therapeutics (SMMT) at 0.00% and Bio-Techne (TECH) at 12.21% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Bio-Techne (TECH) reports revenue growth of -0.38%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Only one side can be read here: Bio-Techne (TECH) reports EPS growth of 152.17%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while Bio-Techne (TECH) at 2.28 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TECH.

Both Summit Therapeutics (SMMT) at 0.04 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Summit Therapeutics (SMMT) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.

Summit Therapeutics (SMMT) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bio-Techne (TECH) trades at 62.74 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

A sales-based read is only available for Bio-Techne (TECH), whose P/S ratio of 9.31 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

Bio-Techne (TECH) at 5.28 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

Valuation Metrics